Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes
Moura F, Berg D, Bellavia A, Dwyer J, Mosenzon O, Scirica B, Wiviott S, Bhatt D, Raz I, Feinberg M, Braunwald E, Morrow D, Sabatine M. Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes. Diabetes Care 2023, 46: 1807-1815. PMID: 37556796, PMCID: PMC10516252, DOI: 10.2337/dc23-0492.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2Kidney disease progressionPredictors of kidney disease progressionAbsolute risk reductionDisease progressionValidation cohortType 2 diabetesSodium-glucose cotransporter 2 inhibitionUrine albumin-to-creatinine ratioAlbumin-to-creatinine ratioEfficacy of dapagliflozinMedian follow-upRisk categoriesMultivariate Cox regressionRelative risk reductionHigh-risk groupAtherosclerotic cardiovascular diseaseSystolic blood pressureRisk reductionMagnitude of benefitDapagliflozin EffectT2D durationCotransporter 2SGLT2 inhibitionStratify riskRISK OF KIDNEY DISEASE PROGRESSION AND EFFICACY OF SGLT2 INHIBITION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
Moura F, Berg D, Bellavia A, Mosenzon O, Dwyer J, Scirica B, Wiviott S, Bhatt D, Raz I, Feinberg M, Morrow D, Sabatine M. RISK OF KIDNEY DISEASE PROGRESSION AND EFFICACY OF SGLT2 INHIBITION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS. Journal Of The American College Of Cardiology 2023, 81: 1808. DOI: 10.1016/s0735-1097(23)02252-0.Peer-Reviewed Original Research